McKesson Raises Outlook but Valuation Concerns Linger

What happened

McKesson executives announced a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions segments, along with a new precision medicine deal to bolster oncology. This positive news aligns with the company's strategic shift toward higher-margin specialty and oncology platforms, which have been key drivers of recent performance. However, the DeepValue master report maintains a 'POTENTIAL SELL' rating, arguing that at $825 the stock already prices in sustained 13-16% adjusted EPS growth, leaving limited upside over 6-18 months. The report highlights that oncology growth is materially acquisition-aided and that headline EPS benefits from one-time gains and aggressive buybacks, while a revived $2.5B West Virginia opioid suit adds legal overhang. Consequently, the raised guidance reinforces operational momentum but does not alleviate valuation concerns, with the report suggesting investors trim above $880 and seek a better entry near $720.

Implication

Despite the raised outlook, the risk-reward remains skewed to the downside given the current valuation; investors should focus on the quality of oncology growth and legal developments. Near-term, monitor whether Oncology & Multispecialty can sustain high-teens profit growth without relying on acquisitions or one-time gains, and track any adverse movement in the West Virginia opioid case. If the stock pulls back below $720 while oncology fundamentals remain intact, it may offer a more compelling entry point. Conversely, if the stock exceeds $880 without a commensurate improvement in organic growth or legal clarity, further trimming is warranted. Overall, maintain a cautious stance until evidence confirms the 13-16% EPS growth target is achievable organically and litigation risks are contained.

Thesis delta

The positive news from McKesson's raised outlook supports the operational strength noted in the DeepValue report, but it does not change the fundamental valuation concern. The thesis remains a 'POTENTIAL SELL' with an attractive entry at $720 and trim above $880, as the current price already reflects robust growth expectations. No shift in the core thesis is warranted at this point; the event reinforces the need for caution given the reliance on acquisitions and legal overhangs.